Application of routine electronic health record databases for pharmacogenetic research

Journal of Internal Medicine

Volumn 275, Issue 6, 2014, Pages 590-604

  Yasmina, A ^a,b   Deneer, V H M ^c   Maitland van der Zee, A H ^a   van Staa, T P ^a,d   de Boer, A ^a   Klungel, O H ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b LAMBUNG MANGKURAT UNIVERSITY   (Indonesia)

^c ST ANTONIUS HOSPITAL   (Netherlands)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Electronic health records; Pharmacogenetics

Indexed keywords

ABACAVIR; ALPHA ADDUCIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NEUROLEPTIC AGENT; ORAL CONTRACEPTIVE AGENT; PHENPROCOUMON; PIOGLITAZONE; PROTON PUMP INHIBITOR; SIMVASTATIN; SULFONYLUREA; WARFARIN;

BLEEDING; CASE CONTROL STUDY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DRUG EXPOSURE; DRUG INTERACTION; DRUG RESPONSE; ELECTRONIC MEDICAL RECORD; FAMILY STUDY; GENE; GENE INTERACTION; GENETICS; GENOTYPE; HEALTH CARE; HEART DEATH; HEART INFARCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY; INFORMATION SYSTEM; MEDICAL RESEARCH; MEDICINE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; PHARMACOGENETIC RESEARCH; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK; ROUTINE ELECTRONIC HEALTH RECORD DATABASE; STENT THROMBOSIS; STUDY DESIGN;

ELECTRONIC HEALTH RECORDS; PHARMACOGENETICS;

ELECTRONIC HEALTH RECORDS; GENETIC ASSOCIATION STUDIES; GENETIC RESEARCH; HUMANS; PHARMACOEPIDEMIOLOGY; PHARMACOGENETICS; RESEARCH DESIGN;

EID: 84902001275     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12226     Document Type: Review

References (85)

1. Ma Q, Lu AYH. Pharmacogenetics, pharmacogenomics, and individualized medicine. Pharmacol Rev 2011; 63: 437-59.
2. Yasuda SU, Zhang L, Huang S-M. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84: 417-23.
3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286: 487-91.
4. Maitland-van der Zee AH, de Boer A, Leufkens HGM. The interface between pharmacoepidemiology and pharmacogenetics. Eur J Pharmacol 2000; 410: 121-30.
5. Eichelbaum M, Ingelman-Sundberg M, Evans WE. Pharmacogenomics and individualized drug therapy. Annu Rev Med 2006; 57: 119-37.
6. Maitland-van der Zee AH, Klungel OH, de Boer A. Pharmacogenetics in health-care practice. Pharm World Sci 2004; 26: 253-5.
7. Henry DA, McGettigan P, Tonkin A, Hennessy S. Basic principles of clinical pharmacology relevant to pharmacoepidemiology studies. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 37-57.
8. Novelli G, Borgiani P, Ciccacci C, Di Daniele N, Sirugo G, Amati MP. Pharmacogenomics: role in medicines approval and clinical use. Public Health Genomics 2010; 13: 284-91.
9. Strom BL. What is pharmacoepidemiology? In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 3-16.
10. Swen JJ, Wilting I, de Goede AL, et al. Pharmacogenetics: from bench to byte. Clin Pharmacol Ther 2008; 83: 781-7.
11. Pulley JM, Denny JC, Peterson JF, et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT Project. Clin Pharmacol Ther 2012; 92: 87-95.
12. O'Donnell PH, Bush A, Spitz J, et al. The 1200 Patients Project: creating a new medical model system for clinical implementation of pharmacogenomics. Clin Pharmacol Ther 2012; 92: 447-9.
13. Steffensen C, Thomsen RW, Vaag A, et al. The Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Project: rationale and planned nationwide studies of genetic predictors, physical exercise, and individualized pharmacological treatment. Clin Epidemiol 2012; 4(Suppl 1): 7-13.
14. Ross S, Anand SS, Joseph P, Paré G. Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues. JRSM Cardiovasc Dis 2012; 1: 1-13.
15. He Y, Hoskins JM, McLeod HL. Copy number variants in pharmacogenetic genes. Trends Mol Med 2011; 17: 244-51.
16. Weber WW. Pharmacogenetics, 2nd edn. New York: Oxford University Press, 2008.
17. Kimmel SE, Leufkens HG, Rebbeck TR. Molecular pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 571-86.
18. Cardon LR, Bell JI. Association study designs for complex diseases. Nat Rev Genet 2001; 2: 91-9.
19. Sanderson S, Emery J, Higgins J. CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis. Genet Med 2005; 7: 97-104.
20. Sim SC, Kacevska M, Ingelman-Sundberg M. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J 2013; 13: 1-11.
21. Yang L, Ge W, Yu F, Zhu H. Impact of VKORC1 gene polymorphism on interindividual and interethnic warfarin dosage requirement-a systematic review and meta analysis. Thromb Res 2010; 125: e159-66.
22. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19*2010; 304: 1821-30.
23. Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. J Am Coll Cardiol 2010; 56: 134-43.
24. Sofi F, Giusti B, Marcucci R, Gori AM, Abbate R, Gensini GF. Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. Pharmacogenomics J 2011; 11: 199-206.
25. Jang JS, Cho KI, Jin HY, et al. Meta-analysis of cytochrome P450 2C19 polymorphism and risk of adverse clinical outcomes among coronary artery disease patients of different ethnic groups treated with clopidogrel. Am J Cardiol 2012; 110: 502-8.
26. Yamaguchi Y, Abe T, Sato Y, Matsubara Y, Moriki T, Murata M. Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: A systematic review and meta-analysis. Platelets 2013; 24: 352-61.
27. Harmsze AM, van Werkum JW, Ten Berg JM, et al. CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study. Eur Heart J 2010; 31: 3046-53.
28. Schalekamp T, Brassé BP, Roijers JF, et al. VKORC1 and CYP2C9 genotypes and phenprocoumon anticoagulation status: interaction between both genotypes affects dose requirement. Clin Pharmacol Ther 2007; 81: 185-93.
29. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-7.
30. Peters BJM, Rodin AS, de Boer A, Maitland-van der Zee AH. Methodological and statistical issues in pharmacogenomics. J Pharm Pharmacol 2010; 62: 161-6.
31. Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet 2006; 7: 781-91.
32. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature 2004; 429: 464-8.
33. Russo R, Capasso M, Paolucci P, Iolascon A. Pediatric pharmacogenetic and pharmacogenomic studies: the current state and future perspectives. Eur J Clin Pharmacol 2011; 67(Suppl 1): S17-27.
34. Goldstein AM, Andrieu N. Detection of interaction involving identified genes: available study designs. J Natl Cancer Inst Monogr 1999; 26: 54.
35. Clayton D, McKeigue PM. Epidemiological methods for studying genes and environmental factors in complex disease. Lancet 2001; 358: 1356-60.
36. Dempfle A, Scherag A, Hein R, Beckmann L, Chang-Claude J, Schäfer H. Gene-environment interactions for complex traits: definitions, methodological requirements and challenges. Eur J Hum Genet 2008; 16: 1164-72.
37. van der Baan FH, Klungel OH, Egberts ACG et al. Pharmacogenetics in randomized controlled trials: considerations for trial design. Pharmacogenomics 2011; 12: 1485-92.
38. Maitland-van der Zee AH, Peters BJM, Lynch AI, et al. The effect of nine common polymorphisms in coagulation factor genes (F2, F5, F7, F12 and F13) on the effectiveness of statins: the GenHAT study. Pharmacogenet Genomics 2009; 19: 338-44.
39. Aquilante CL, Kosmiski LA, Bourne DWA, et al. Impact of the CYP2C8*3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br J Clin Pharmacol 2013; 75: 217-26.
40. Gallo P, Chuang-Stein C, Dragalin V, Gaydos B, Krams M, Pinheiro J. Adaptive designs in clinical drug development - an executive summary of the PhRMA Working Group. J Biopharm Stat 2006; 16: 275-83.
41. Hung HMJ, O'Neill RT, Wang S-J, Lawrence J. A regulatory view on adaptive/flexible clinical trial design. Biom J 2006; 48: 565-73.
42. van der Baan FH, Knol MJ, Klungel OH, Egberts ACG, Grobbee DE, Roes KCB. Potential of adaptive clinical trial designs in pharmacogenetic research. Pharmacogenomics 2012; 13: 571-8.
43. Mallal S, Phillips E, Carosi G, et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
44. Hong EP, Park JW. Sample size and statistical power calculation in genetic association studies. Genomics Inform 2012; 10: 117-22.
45. Spencer CCA, Su Z, Donnelly P, Marchini J. Designing genome-wide association studies: sample size, power, imputation, and the choice of genotyping chip. PLoS Genet 2009; 5: e1000477.
46. Evans DM, Purcell S. Power calculations in genetic studies. Cold Spring Harb Protoc 2012; 2012: 664-74.
47. Weinberg CR, Umbach DM. Choosing a retrospective design to assess joint genetic and environmental contributions to risk. Am J Epidemiol 2000; 152: 197-203.
48. Berbano EP, Baxi N. Impact of patient selection in various study designs: identifying potential bias in clinical results. South Med J 2012; 105: 149-55.
49. Strom BL. Study designs available for pharmacoepidemiology studies. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 17-28.
50. Harmsze AM, van Werkum JW, Souverein PC, et al. Combined influence of proton-pump inhibitors, calcium-channel blockers and CYP2C19*2 on on-treatment platelet reactivity and on the occurrence of atherothrombotic events after percutaneous coronary intervention. J Thromb Haemost 2011; 9: 1892-901.
51. Elens L, Becker ML, Haufroid V, et al. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenet Genomics 2011; 21: 861-6.
52. Andrieu N, Goldstein AM. Epidemiologic and genetic approaches in the study of gene-environment interaction: an overview of available methods. Epidemiol Rev 1998; 20: 137-47.
53. Tripepi G, Jager KJ, Dekker FW, Zoccali C. Selection bias and information bias in clinical research. Nephron Clin Pract 2010; 115: c94-9.
54. Garcia-Closas M, Thompson WD, Robins JM. Differential misclassification and the assessment of gene-environment interactions in case-control studies. Am J Epidemiol 1998; 147: 426-33.
55. Peters BJM, Pett H, Klungel OH, et al. Genetic variability within the cholesterol lowering pathway and the effectiveness of statins in reducing the risk of MI. Atherosclerosis 2011; 217: 458-64.
56. Biss TT, Avery PJ, Brandão LR, et al. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 2012; 119: 868-73.
57. Hamajima N, Yuasa H, Matsuo K, Kurobe Y. Detection of gene-environment interaction by case-only studies. Jpn J Clin Oncol 1999; 29: 490-3.
58. Gatto NM, Campbell UB, Rundle AG, Ahsan H. Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias. Int J Epidemiol 2004; 33: 1014-24.
59. Lynch AI, Irvin MR, Boerwinkle E, et al. RYR3 gene polymorphisms and cardiovascular disease outcomes in the context of antihypertensive treatment. Pharmacogenomics J 2013; 13: 330-4.
60. Mega JL, Close SL, Wiviott SD, et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360: 354-62.
61. Holmes MV, Perel P, Shah T, Hingorani AD, Casas JP. CYP2C19*2011; 306: 2704-14.
62. Saunders KW, Davis RL, Stergachis A. Group Health Cooperative. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 223-39.
63. Leufkens HG, Urquhart J. Automated pharmacy record linkage in the Netherlands. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 311-22.
64. Wei L, Parkinson J, MacDonald TM. The Tayside Medicines Monitoring Unit (MEMO). In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 323-36.
65. Gelfand JM, Margolid DJ, Dattani H. The UK General Practice Research Database. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 338-46.
66. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287: 1680-9.
67. Pearson ER, Donnelly LA, Kimber C, et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas. Diabetes 2007; 56: 2178-82.
68. Schillevoort I, de Boer A, van der Weide J et al. Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics 2002; 12: 235-40.
69. Bozkurt Ö, Verschuren WMM, van Wieren-de Wijer BMA, et al. Genetic variation in the renin-angiotensin system modifies the beneficial effects of ACE inhibitors on the risk of diabetes mellitus among hypertensives. J Hum Hypertens 2008; 22: 774-80.
70. Carr DF, O'Meara H, Jorgensen AL, et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the Clinical Practice Research Datalink. Clin Pharmacol Ther 2013; 94: 695-701.
71. van Wieren-de Wijer DBMA, Maitland-van der Zee AH, de Boer A, et al. Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment. Pharm World Sci 2009; 31: 158-64.
72. Privacybeleid Mondriaan Project. Mondriaan Project, 2011. URL: http://www.projectmondriaan.nl/privacy.html [5 February 2013].
73. Evans JMM, McNaughton D, Donnan PT, MacDonald TM. Pharmacoepidemiological research at the Medicines Monitoring Unit, Scotland: data protection and confidentiality. Pharmacoepidemiol Drug Saf 2001; 10: 669-73.
74. Tannen RL, Weiner MG, Xie D. Use of primary care electronic medical record database in drug efficacy research on cardiovascular outcomes: comparison of database and randomised controlled trial findings. BMJ 2009; 338: b81. doi:10.1136/bmj.b81.
75. Wing K, Douglas I, Bhaskaran K, et al. Development of predictive genetic tests for improving the safety of new medicines: the utilization of routinely collected electronic health records. Drug Discov Today 2013; pii: S1359-6446(13)00397-8. doi: 10.1016/j.drudis.2013.11.003. [Epub ahead of print]
76. Pirmohamed M, Aithal GP, Behr E, Daly A, Roden D. The Phenotype Standardization Project: improving pharmacogenetic studies of serious adverse drug reactions. Clin Pharmacol Ther 2011; 89: 784-5.
77. Strom BL. Overview of automated databases in pharmacoepidemiology. In: Strom BL, ed. Pharmacoepidemiology, 4th edn. West Sussex: John Wiley & Sons Ltd., 2006; 219-22.
78. Wilke RA, Xu H, Denny JC, et al. The emerging role of electronic medical records in pharmacogenomics. Clin Pharmacol Ther 2011; 89: 379-86.
79. Fost N. Ethical implications of screening asymptomatic individuals. FASEB J 1992; 6: 2813-7.
80. Green MJ, Botkin JR. "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Ann Intern Med 2003; 138: 571-5.
81. Feldman EA. The Genetic Information Nondiscrimination Act (GINA): public policy and medical practice in the age of personalized medicine. J Gen Intern Med 2012; 27: 743-6.
82. Lin Z, Owen AB, Altman RB. Genomic research and human subject privacy. Science 2004; 305: 183.
83. Harper AR, Topol EJ. Pharmacogenomics in clinical practice and drug development. Nat Biotechnol 2012; 30: 1117-24.
84. Agúndez JA, Abad-Santos F, Aldea A, et al. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Front Genet 2012; 3: 273.
85. Love TE, Cebul RD, Einstadter D, et al. Electronic medical record-assisted design of a cluster-randomized trial to improve diabetes care and outcomes. J Gen Intern Med 2008; 23: 383-91.